Literature DB >> 15624511

Computed tomography perfusion of the liver: assessment of pure portal blood flow studied with CT perfusion during superior mesenteric arterial portography.

H Kojima1, N Tanigawa, A Komemushi, S Kariya, S Sawada.   

Abstract

PURPOSE: To quantitatively assess the portal component of hepatic blood flow using computed tomography (CT) perfusion studies during superior mesenteric arterial portography.
MATERIAL AND METHODS: Thirty-four patients with hepatocellular carcinoma and liver cirrhosis (LC) and 13 patients with liver metastasis without chronic liver disease were enrolled in this study. Ten milliliters of a non-ionic contrast medium (150 mg I) was injected at a rate of 5 ml/s via a catheter placed in the superior mesenteric artery. Single-slice cine CT images at the level of the main trunk or the right/left main trunk of the portal vein were acquired over 40 s. The deconvolution method was then used on these CT images to measure blood flow (BF), blood volume (BV), and mean transit time (MTT) in (a) liver parenchyma in patients with HCC and liver cirrhosis; (b) liver parenchyma in patients with liver metastasis without cirrhosis; (c) directly in the HCC; and (d) directly in one of the metastases.
RESULTS: In 34 LC patients (a), BF, BV, and MTT in the liver parenchyma were 44.7+/-24.5 ml/min/100 g, 3.9+/-2.4 ml/100 g, and 10.9+/-5.5 s, respectively. In 13 patients without cirrhosis (b), BF, BV, and MTT in the liver parenchyma were 89.6+/-52.0 ml/min/100 g, 6.3+/-3.2 ml/100 g, and 8.7+/-3.6 sec, respectively. A significant difference in BF and BV was seen in patients with liver cirrhosis compared to those without cirrhosis. BF, BV, and MTT measured directly in HCC (c) were 6.5+/-4.5 ml/min/100 g, 0.4+/-0.4 ml/100 g, and 3.0+/-3.1 sec respectively, and BF, BV, and MTT in liver metastases (d) were 19.3+/-21.7 ml/min/100 g, 0.6+/-0.8 ml/100 g, and 1.8+/-1.6 s, respectively.
CONCLUSION: CT perfusion studies during superior mesenteric arterial portography allow quantitative assessment of pure portal blood flow in the liver.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15624511     DOI: 10.1080/02841850410001385

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  6 in total

1.  Three-dimensional perfusion imaging of hepatocellular carcinoma using 256-slice multidetector-row computed tomography.

Authors:  Tatsushi Kobayashi; Takayuki Hayashi; Shintaro Funabasama; Shinsuke Tsukagoshi; Manabu Minami; Noriyuki Moriyama
Journal:  Radiat Med       Date:  2008-11-22

2.  A semi-automatic method for the extraction of the portal venous input function in quantitative dynamic contrast-enhanced CT of the liver.

Authors:  Andrew B Gill; Nicholas J Hilliard; Simon T Hilliard; Martin J Graves; David J Lomas; Ashley Shaw
Journal:  Br J Radiol       Date:  2017-06-20       Impact factor: 3.039

3.  A comparative study between arterial spin labeling and CT perfusion methods on hepatic portal venous flow.

Authors:  Yoshiaki Katada; Toshiro Shukuya; Miho Kawashima; Miwako Nozaki; Hiroshi Imai; Takeshi Natori; Masaya Tamano
Journal:  Jpn J Radiol       Date:  2012-09-19       Impact factor: 2.374

4.  Triple-phase computed tomography during arterial portography with bolus tracking for hepatic tumors.

Authors:  Motoki Nakai; Morio Sato; Akira Ikoma; Kohei Nakata; Shinya Sahara; Isao Takasaka; Hiroki Minamiguchi; Nobuyuki Kawai; Tetsuro Sonomura; Kazushi Kishi
Journal:  Jpn J Radiol       Date:  2010-02-26       Impact factor: 2.374

5.  Mesenteric and splenic contributions to portal venous CT perfusion in hepatic diffuse disease.

Authors:  Hongzan Sun; Zaiming Lu; Hongyuan Liang; Jun Xin; Yuying Gao; Qiyong Guo
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

6.  Establishing models of portal vein occlusion and evaluating value of multi-slice CT in hepatic VX2 tumor in rabbits.

Authors:  Yue-Yong Qi; Li-Guang Zou; Ping Liang; Dong Zhang
Journal:  World J Gastroenterol       Date:  2007-06-28       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.